Company intelligence / Profile preview

AdRx Digital

Thousand Oaks, California, United Stateslinkedin.com ↗

Ownership: Private
Development stage: Other

Overview

The company has developed novel small molecule modulators that disrupt pathological protein-protein interactions involved in neurodegenerative diseases. Their lead programs are preclinical, with a focus on halting or reversing aggregation of tau, TDP‑43, and alpha-synuclein proteins. Patent filings include tau aggregation peptide inhibitors for Alzheimer's disease. No clinical results have been reported yet.

Therapeutic areas: Neurology
Modalities: Small moleculePeptides
Industry: Biotech

Partnerships

MRL Ventures (investor; no major pharma partnerships disclosed)

Beyond the preview

Go deeper on AdRx Digital.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AdRx Digital.

Explore the full profile